Therapeutic approaches involving the selective modulation of SIRT activity are likely to enhance CD8+ T cell responses, either by inhibition—for example, SIRT2 and SIRT5 in LUAD, or by activation—for instance, SIRT4 in bladder cancer—to overcome resistance to immunotherapy. The gene discussed is CD8A; the disease is urinary bladder carcinoma.